BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 9226467)

  • 1. [Augmentation of vaccination effects of PGE2-producing tumor cells by transfection with cytokine genes].
    Ohiro Y
    Hokkaido Igaku Zasshi; 1997 May; 72(3):273-84. PubMed ID: 9226467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased in vitro and in vivo tumoricidal activity of a macrophage cell line genetically engineered to express IFN-gamma, IL-4, IL-6, or TNF-alpha.
    Nishihara K; Barth RF; Wilkie N; Lang JC; Oda Y; Kikuchi H; Everson MP; Lotze MT
    Cancer Gene Ther; 1995 Jun; 2(2):113-24. PubMed ID: 7621259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory mechanisms for production of IFN-gamma and TNF by antitumor T cells or macrophages in the tumor-bearing state.
    Yamamoto N; Zou JP; Li XF; Takenaka H; Noda S; Fujii T; Ono S; Kobayashi Y; Mukaida N; Matsushima K
    J Immunol; 1995 Mar; 154(5):2281-90. PubMed ID: 7868900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-alpha, IFN-gamma, and TNF-alpha.
    Musiani P; Allione A; Modica A; Lollini PL; Giovarelli M; Cavallo F; Belardelli F; Forni G; Modesti A
    Lab Invest; 1996 Jan; 74(1):146-57. PubMed ID: 8569177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokine gene-modified tumor cells for prophylactic and therapeutic vaccination: IL-2, IFN-gamma, or combination IL-2 + IFN-gamma.
    Kircheis R; Küpcü Z; Wallner G; Wagner E
    Cytokines Cell Mol Ther; 1998 Jun; 4(2):95-103. PubMed ID: 9681248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IFN-gamma-independent synergistic effects of IL-12 and IL-15 induce anti-tumor immune responses in syngeneic mice.
    Comes A; Di Carlo E; Musiani P; Rosso O; Meazza R; Chiodoni C; Colombo MP; Ferrini S
    Eur J Immunol; 2002 Jul; 32(7):1914-23. PubMed ID: 12115611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
    Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
    J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance of Ha-ras oncogene-induced progressor tumor variants to tumor necrosis factor and interferon-gamma.
    Fernandez A; Chen PW; Aggarwal BB; Ananthaswamy HN
    Lymphokine Cytokine Res; 1992 Apr; 11(2):79-85. PubMed ID: 1581420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effect of interleukin (IL)-12 in the absence of endogenous IFN-gamma: a role for intrinsic tumor immunogenicity and IL-15.
    Gri G; Chiodoni C; Gallo E; Stoppacciaro A; Liew FY; Colombo MP
    Cancer Res; 2002 Aug; 62(15):4390-7. PubMed ID: 12154045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Ganoderma polysaccharides antagonize prostaglandin E2-induced suppression of murine splenocyte IFN-gamma and TNF-alpha mRNA expression].
    Zhang Q; Lei LS; Zhu ZG; Yu CL; Wu SG
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jun; 26(6):780-3. PubMed ID: 16793600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful immunogene therapy using colon cancer cells (colon 26) transfected with plasmid vector containing mature interleukin-18 cDNA and the Igkappa leader sequence.
    Yoshimura K; Hazama S; Iizuka N; Yoshino S; Yamamoto K; Muraguchi M; Ohmoto Y; Noma T; Oka M
    Cancer Gene Ther; 2001 Jan; 8(1):9-16. PubMed ID: 11219497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects.
    Osaki T; Péron JM; Cai Q; Okamura H; Robbins PD; Kurimoto M; Lotze MT; Tahara H
    J Immunol; 1998 Feb; 160(4):1742-9. PubMed ID: 9469432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experimental cancer cachexia: the role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-dependent cachexia.
    Cahlin C; Körner A; Axelsson H; Wang W; Lundholm K; Svanberg E
    Cancer Res; 2000 Oct; 60(19):5488-93. PubMed ID: 11034092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic administration of rIL-12 synergistically enhances the therapeutic effect of a TNF gene-transduced cancer vaccine.
    Taniguchi F; Yamagishi H; Fujiwara H; Ueda Y; Fuji N; Yoshimura T; Oka T
    Gene Ther; 1998 Dec; 5(12):1677-84. PubMed ID: 10023447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4-1BBL enhances anti-tumor responses in the presence or absence of CD28 but CD28 is required for protective immunity against parental tumors.
    Guinn BA; Bertram EM; DeBenedette MA; Berinstein NL; Watts TH
    Cell Immunol; 2001 May; 210(1):56-65. PubMed ID: 11485353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IFN-alpha 1 gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8+ T cell-mediated tumor rejection and development of antitumor immunity. Comparative studies with IFN-gamma-producing TS/A cells.
    Ferrantini M; Giovarelli M; Modesti A; Musiani P; Modica A; Venditti M; Peretti E; Lollini PL; Nanni P; Forni G
    J Immunol; 1994 Nov; 153(10):4604-15. PubMed ID: 7963533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of immune responses in the eradication of IL-1 alpha gene-transduced tumour cells: mechanisms of tumour rejection and immunotherapeutical implications.
    Apte RN; Douvdevani A; Zoller M; White RM; Dvorkin T; Shimoni N; Huleihel M; Fima E; Hacham M; Voronov E
    Folia Biol (Praha); 1994; 40(1-2):1-18. PubMed ID: 7958060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insertion of the IL-2 gene decreases tumorigenicity of murine fibrosarcoma.
    Kuśnierczyk H; Załecki P; Pajtasz-Piasecka E; Radzikowski C
    Arch Immunol Ther Exp (Warsz); 1998; 46(4):259-65. PubMed ID: 9779293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating levels of IL-10 are critically related to growth and rejection patterns of murine mastocytoma cells.
    Grohmann U; Silla S; Belladonna ML; Bianchi R; Orabona C; Puccetti P; Fioretti MC
    Cell Immunol; 1997 Nov; 181(2):109-19. PubMed ID: 9398398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene therapy for Lewis lung carcinoma with tumor necrosis factor and interleukin 2 cDNAs co-transfected subline.
    Ohira T; Ohe Y; Heike Y; Podack ER; Olsen KJ; Nishio K; Nishio M; Miyahara Y; Funayama Y; Ogasawara H
    Gene Ther; 1994 Jul; 1(4):269-75. PubMed ID: 7584091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.